Skip to main content
. 2020 Mar 15;8(1):e000943. doi: 10.1136/bmjdrc-2019-000943

Figure 3.

Figure 3

Impact of exposure to evacetrapib on the composite (A) and triple composite endpoint (B) outcome among patients with diabetes mellitus randomized to treatment with evacetrapib or placebo. CV, cardiovascular; DM, diabetes mellitus; MI, myocardial infarction; UA, unstable angina.